Italia markets closed

Dow Jones
39.847,87
+289,76(+0,73%)
Nasdaq
16.740,12
+228,94(+1,39%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0883
+0,0061(+0,57%)
Bitcoin EUR
60.615,42
+4.048,98(+7,16%)
CMC Crypto 200
1.383,97
+116,02(+9,15%)

NVCR Dec 2025 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

7,70

0,00

(0,00%)

In data: 01:26PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in